Deleted Tweets From Scott Gottlieb, R-D.C.

RT @_bakulpatel: I want to acknowledge the #FDAPrecert team for their hard work on this program throughout 2018. Great job guys! Looking forward to next steps in 2019. #DigitalHealth https://t.co/HdegDz6az8

@SarahKarlin The funded vs unfunded hiring probably tracks user fee allocations as a percent of total budget fairly closely. So it’s about 50/50. Obviously fluctuates week to week. User fees only get us 1-2 months depending on which user fee program, with PDUFA running out first, MDUFMA last.

#FDA believes safety is a priority before and after approval and maintaining the safety of drugs Americans rely on is complex because new safety issues can arise at any time – regardless of how long a drug has been in use or its past record of safety. https://t.co/rTMS01a5XR

We know drug safety issues will always exist. Our job is to detect them when we are able, prevent them from affecting consumers when possible, and to do all we can to mitigate and manage them as they arise. https://t.co/rTMS01a5XR

RT @matthewherper: My story on the new office @SGottliebFDA is creating to push forward personalized medicine is now in front of the STAT paywall. https://t.co/5ySY3mMEbw

The safety of drugs that Americans rely on is a top priority for #FDA. Our #FDAVoices post today discusses the work FDA has done in 2018 to make sure drugs we approve are not only effective, but safe. https://t.co/rTMS01a5XR

Our annual report, Drug Safety Priorities 2018 illustrates how #FDA CDER approaches drug safety in many ways. It provides updates on our ongoing initiatives, discusses new work, and highlights last year’s safety-related milestones and achievements. https://t.co/rTMS01a5XR

THREAD - UPDATE ON SHUTDOWN: We’re making decisions across our portfolio to focus #FDA resources to key consumer protection functions. One action we’ll be taking is to re-allocate user fee money from certain pre-market drug review work to post market drug safety surveillance.

We’ll release more details on these re-allocations in coming days. We’re systematically reviewing our portfolio and making sure that our safety functions remain resourced as best they can, for as long as they can. Our consumer protection role is our most critical mission.

RT @fredhutch: .@US_FDA plans to create a new office to modernize the drug review process with a standardized approach to personalized data, digital data and patient reports, commissioner @SGottliebFDA says. https://t.co/yOU60Xlmvw #JPM19

All of our work at the #FDA is critical, so nothing we stand down is unimportant. But the functions that can most directly impact consumer safety will continue, to the best of our abilities, subject to the legal and financial limitations of the current circumstances .

Everyone who works at #FDA are part of something very special, and their contributions across our mandate make a real difference. This dedication to a shared mission guides us through challenging times, when many colleagues are facing the strain and uncertainty of lapsed pay. https://t.co/feAbKnreAc

During the shutdown, #FDA continues its work reviewing medical devices imported into the U.S. to determine the potential risk to human health. We currently are not experiencing any delays in our entry review process.

THREAD: Today #FDA issued a five-year strategic plan for the Sentinel System, which lays out the major goals associated with the future of Sentinel and serves as a roadmap to guide the development of the system over the next five years. https://t.co/deST7thpYu

.@AC360 please have your guest Sara Doerr contact me. Nobody should be unable to access a clinical trial or compassionate use drug owing to the funding lapse. We will help her. Our drug review staff remains at their posts across our centers. CNN never contacted us before airing.

This is a unique agency with a mission that makes a measurable difference for Americans. Our entire portfolio matters, and each of our colleagues are critical. While all of our work is important, we’re dedicated first and foremost to our work that protects American lives.

Read my latest #FDAVoices piece, co-bylined with CDERs Dr. Gerald Dal Pan, which discusses the mission-critical role of electronic surveillance to ensure safety and effectiveness of medical products. https://t.co/deST7thpYu

Sentinel is an integral part of FDA’s safety monitoring efforts. It’s a critical engine for methodological innovation, and a platform to advance the science of real world evidence. https://t.co/deST7thpYu

One of #FDAs most important tools is electronic safety surveillance – the ability to access and analyze data across millions of patient experiences with the medical products they use – while protecting privacy of individual health care records. https://t.co/deST7thpYu

THREAD: Food Safety During Shutdown: We’re taking steps to expand the scope of food safety surveillance inspections we’re doing during the shutdown to make sure we continue inspecting high risk food facilities. 31% of our inventory of domestic inspections are considered high risk

RT @_bakulpatel: I want to acknowledge the #FDAPrecert team for their hard work on this program throughout 2018. Great job guys! Looking forward to next steps in 2019. #DigitalHealth https://t.co/HdegDz6az8

@SarahKarlin The funded vs unfunded hiring probably tracks user fee allocations as a percent of total budget fairly closely. So it’s about 50/50. Obviously fluctuates week to week. User fees only get us 1-2 months depending on which user fee program, with PDUFA running out first, MDUFMA last.

#FDA believes safety is a priority before and after approval and maintaining the safety of drugs Americans rely on is complex because new safety issues can arise at any time – regardless of how long a drug has been in use or its past record of safety. https://t.co/rTMS01a5XR

We know drug safety issues will always exist. Our job is to detect them when we are able, prevent them from affecting consumers when possible, and to do all we can to mitigate and manage them as they arise. https://t.co/rTMS01a5XR

RT @matthewherper: My story on the new office @SGottliebFDA is creating to push forward personalized medicine is now in front of the STAT paywall. https://t.co/5ySY3mMEbw

The safety of drugs that Americans rely on is a top priority for #FDA. Our #FDAVoices post today discusses the work FDA has done in 2018 to make sure drugs we approve are not only effective, but safe. https://t.co/rTMS01a5XR

Our annual report, Drug Safety Priorities 2018 illustrates how #FDA CDER approaches drug safety in many ways. It provides updates on our ongoing initiatives, discusses new work, and highlights last year’s safety-related milestones and achievements. https://t.co/rTMS01a5XR

THREAD - UPDATE ON SHUTDOWN: We’re making decisions across our portfolio to focus #FDA resources to key consumer protection functions. One action we’ll be taking is to re-allocate user fee money from certain pre-market drug review work to post market drug safety surveillance.

We’ll release more details on these re-allocations in coming days. We’re systematically reviewing our portfolio and making sure that our safety functions remain resourced as best they can, for as long as they can. Our consumer protection role is our most critical mission.

RT @fredhutch: .@US_FDA plans to create a new office to modernize the drug review process with a standardized approach to personalized data, digital data and patient reports, commissioner @SGottliebFDA says. https://t.co/yOU60Xlmvw #JPM19

All of our work at the #FDA is critical, so nothing we stand down is unimportant. But the functions that can most directly impact consumer safety will continue, to the best of our abilities, subject to the legal and financial limitations of the current circumstances .

Everyone who works at #FDA are part of something very special, and their contributions across our mandate make a real difference. This dedication to a shared mission guides us through challenging times, when many colleagues are facing the strain and uncertainty of lapsed pay. https://t.co/feAbKnreAc

During the shutdown, #FDA continues its work reviewing medical devices imported into the U.S. to determine the potential risk to human health. We currently are not experiencing any delays in our entry review process.

THREAD: Today #FDA issued a five-year strategic plan for the Sentinel System, which lays out the major goals associated with the future of Sentinel and serves as a roadmap to guide the development of the system over the next five years. https://t.co/deST7thpYu

.@AC360 please have your guest Sara Doerr contact me. Nobody should be unable to access a clinical trial or compassionate use drug owing to the funding lapse. We will help her. Our drug review staff remains at their posts across our centers. CNN never contacted us before airing.

This is a unique agency with a mission that makes a measurable difference for Americans. Our entire portfolio matters, and each of our colleagues are critical. While all of our work is important, we’re dedicated first and foremost to our work that protects American lives.

Read my latest #FDAVoices piece, co-bylined with CDERs Dr. Gerald Dal Pan, which discusses the mission-critical role of electronic surveillance to ensure safety and effectiveness of medical products. https://t.co/deST7thpYu

Sentinel is an integral part of FDA’s safety monitoring efforts. It’s a critical engine for methodological innovation, and a platform to advance the science of real world evidence. https://t.co/deST7thpYu

One of #FDAs most important tools is electronic safety surveillance – the ability to access and analyze data across millions of patient experiences with the medical products they use – while protecting privacy of individual health care records. https://t.co/deST7thpYu

THREAD: Food Safety During Shutdown: We’re taking steps to expand the scope of food safety surveillance inspections we’re doing during the shutdown to make sure we continue inspecting high risk food facilities. 31% of our inventory of domestic inspections are considered high risk